BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23109727)

  • 1. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1.
    Lee JM; Park H; Noh AL; Kang JH; Chen L; Zheng T; Lee J; Ji SY; Jang CY; Shin CS; Ha H; Lee ZH; Park HY; Lee DS; Yim M
    J Immunol; 2012 Dec; 189(11):5284-92. PubMed ID: 23109727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression.
    Kang JH; Ting Z; Moon MR; Sim JS; Lee JM; Doh KE; Hong S; Cui M; Choi S; Chang HW; Park Choo HY; Yim M
    Bioorg Med Chem; 2015 Nov; 23(21):7069-78. PubMed ID: 26432605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminocoumarins inhibit osteoclast differentiation and bone resorption via downregulation of nuclear factor of activated T cells c1.
    Zheng T; Noh AL; Park H; Yim M
    Biochem Pharmacol; 2013 Feb; 85(3):417-25. PubMed ID: 23123663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast differentiation and bone resorption.
    Zheng C; Shi X
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S64-S70. PubMed ID: 30183378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
    Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-osteoclastogenic activity of matairesinol via suppression of p38/ERK-NFATc1 signaling axis.
    Choi SW; Park KI; Yeon JT; Ryu BJ; Kim KJ; Kim SH
    BMC Complement Altern Med; 2014 Jan; 14():35. PubMed ID: 24444335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
    Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decursin from Angelica gigas suppresses RANKL-induced osteoclast formation and bone loss.
    Wang X; Zheng T; Kang JH; Li H; Cho H; Jeon R; Ryu JH; Yim M
    Eur J Pharmacol; 2016 Mar; 774():34-42. PubMed ID: 26825541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors.
    Strålberg F; Kassem A; Kasprzykowski F; Abrahamson M; Grubb A; Lindholm C; Lerner UH
    J Leukoc Biol; 2017 May; 101(5):1233-1243. PubMed ID: 28196851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.